Switch theme
Sign up to access all valuation multiples
SKAN Group AG is a market and technological company for isolators, cleanroom devices, and decontamination processes for the aseptic production of biopharmaceutical substances. Its core competency is the design and development of process isolators for the aseptic filling of biopharmaceutical products. The company offers its customers process support, services, and consumables. Its products include biological indicators, isolators, Laboratory/cleanroom equipment, laminar flow, safety workbenches, and transfer systems. The Firm has three operating segments: Equipment & solutions, Services & Consumables, and Other. The company generates the majority of its revenue from the Equipment & solutions segment. Geographically, the company derives revenue from Asia, Europe, Americas, and Other regions.
1968
1.5K+
LTM Revenue $465M
LTM EBITDA $72.8M
$1.9B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
SKAN Group has a last 12-month revenue (LTM) of $465M and a last 12-month EBITDA of $72.8M.
In the most recent fiscal year, SKAN Group achieved revenue of $434M and an EBITDA of $71.7M.
SKAN Group expects next 12-month revenue of XXX and NTM EBITDA of XXX
See SKAN Group valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $465M | XXX | $434M | XXX | XXX | XXX |
| Gross Profit | $465M | XXX | $319M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 74% | XXX | XXX | XXX |
| EBITDA | $72.8M | XXX | $71.7M | XXX | XXX | XXX |
| EBITDA Margin | 16% | XXX | 17% | XXX | XXX | XXX |
| EBIT | $54.9M | XXX | $53.4M | XXX | XXX | XXX |
| EBIT Margin | 12% | XXX | 12% | XXX | XXX | XXX |
| Net Profit | $48.5M | XXX | $46.6M | XXX | XXX | XXX |
| Net Margin | 10% | XXX | 11% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, SKAN Group's stock price is CHF 72 (or $86).
SKAN Group has current market cap of CHF 1.6B (or $1.9B), and EV of CHF 1.6B (or $1.9B).
See SKAN Group trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.9B | $1.9B | XXX | XXX | XXX | XXX | $2.13 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, SKAN Group has market cap of $1.9B and EV of $1.9B.
SKAN Group's trades at 4.3x EV/Revenue multiple, and 26.2x EV/EBITDA.
Equity research analysts estimate SKAN Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
SKAN Group has a P/E ratio of 40.0x.
See valuation multiples for SKAN Group and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.9B | XXX | $1.9B | XXX | XXX | XXX |
| EV (current) | $1.9B | XXX | $1.9B | XXX | XXX | XXX |
| EV/Revenue | 4.0x | XXX | 4.3x | XXX | XXX | XXX |
| EV/EBITDA | 25.8x | XXX | 26.2x | XXX | XXX | XXX |
| EV/EBIT | 34.2x | XXX | 35.2x | XXX | XXX | XXX |
| EV/Gross Profit | 4.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | 40.0x | XXX | 41.7x | XXX | XXX | XXX |
| EV/FCF | 88.8x | XXX | -220.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSKAN Group's last 12 month revenue growth is 18%
SKAN Group's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.
SKAN Group's rule of 40 is 32% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
SKAN Group's rule of X is 60% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for SKAN Group and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 18% | XXX | 18% | XXX | XXX | XXX |
| EBITDA Margin | 16% | XXX | 17% | XXX | XXX | XXX |
| EBITDA Growth | 18% | XXX | 20% | XXX | XXX | XXX |
| Rule of 40 | 32% | XXX | 34% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 60% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 1% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 61% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
SKAN Group acquired XXX companies to date.
Last acquisition by SKAN Group was XXXXXXXX, XXXXX XXXXX XXXXXX . SKAN Group acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was SKAN Group founded? | SKAN Group was founded in 1968. |
| Where is SKAN Group headquartered? | SKAN Group is headquartered in Switzerland. |
| How many employees does SKAN Group have? | As of today, SKAN Group has 1.5K+ employees. |
| Who is the CEO of SKAN Group? | SKAN Group's CEO is Mr. Thomas Huber. |
| Is SKAN Group publicy listed? | Yes, SKAN Group is a public company listed on SWX. |
| What is the stock symbol of SKAN Group? | SKAN Group trades under SKAN ticker. |
| When did SKAN Group go public? | SKAN Group went public in 2021. |
| Who are competitors of SKAN Group? | Similar companies to SKAN Group include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of SKAN Group? | SKAN Group's current market cap is $1.9B |
| What is the current revenue of SKAN Group? | SKAN Group's last 12 months revenue is $465M. |
| What is the current revenue growth of SKAN Group? | SKAN Group revenue growth (NTM/LTM) is 18%. |
| What is the current EV/Revenue multiple of SKAN Group? | Current revenue multiple of SKAN Group is 4.0x. |
| Is SKAN Group profitable? | Yes, SKAN Group is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of SKAN Group? | SKAN Group's last 12 months EBITDA is $72.8M. |
| What is SKAN Group's EBITDA margin? | SKAN Group's last 12 months EBITDA margin is 16%. |
| What is the current EV/EBITDA multiple of SKAN Group? | Current EBITDA multiple of SKAN Group is 25.8x. |
| What is the current FCF of SKAN Group? | SKAN Group's last 12 months FCF is $21.2M. |
| What is SKAN Group's FCF margin? | SKAN Group's last 12 months FCF margin is 5%. |
| What is the current EV/FCF multiple of SKAN Group? | Current FCF multiple of SKAN Group is 88.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
